What Happened?
Radnor, PA-based Marinus Pharmaceuticals Appointed Steven Pfanstiel as Chief Financial Officer
Date of management change: June 02, 2021
Radnor, PA-based Marinus Pharmaceuticals Appointed Steven Pfanstiel as Chief Financial Officer
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.
Steven Pfanstiel is Chief Financial Officer at Marinus Pharmaceuticals. Previously, Steven held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Burford Mark, Joyce Erin, Latham Desiree, Otremba Lou, Martin Stephen, Lacroix Martha S, Douglas Antanio, Robertson John, Shea Maureen, M Rick, Carrabba Brandon
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.